Henry Schein reported third‑quarter earnings on November 3 that beat profit expectations but missed revenue, sending the price to $87.16, just under the swing‑zone resistance of $87.84. The stock remains above its 50‑day average of $86.09 and the 40‑week trend line, keeping the longer‑term uptrend intact. A daily close above $87.84 on volume above the 20‑day average would signal the next leg of the move, but the breakout math falls short of a 3‑to‑1 reward‑to‑risk ratio.
Why it matters
The earnings release showed non‑GAAP EPS of $1.56, well above the $1.36 consensus, while revenue of $3.47 billion fell just short of the $3.48 billion forecast. Management highlighted market‑share gains and margin expansion, and raised its 2026 non‑GAAP EPS guidance to $5.50‑$5.56. The beat on earnings was quickly offset by the revenue miss, which explains why the shares slipped nearly 5 % in intraday trading despite the profit surprise.
Most of the price reaction was driven by the stock itself. Over the past five days the stock rose 0.62 % while the S&P 500 fell 2.70 % and the healthcare sector ETF XLV was essentially flat (‑0.04 %). The attribution numbers show that HSIC outperformed the market by 4.0 % versus the S&P 500 and lagged XLV by 5.6 % over the same period, indicating that the move was largely a stock‑specific response to the earnings mix rather than a sector‑wide swing.
Analysts remain broadly positive: fifteen analysts rate the stock “buy” with a consensus target of $96.6, implying a 9.8 % discount to the mean target. The spread between the low ($64) and high ($110) targets is wide, reflecting divergent views on how the growth narrative will play out.
Debate in the market is split. A NASDAQ article argues that HSIC is a solid growth stock, pointing to projected earnings growth of 10.6 % versus the industry’s 5.3 % and an asset‑utilization ratio of 1.21 against the sector’s 0.77 NASDAQ. Conversely, investors note that discretionary dental spending is under pressure, as highlighted by a Benzinga piece that flagged a slowdown in elective procedures despite strong merchandise sales Benzinga. The mixed signals keep conviction at a medium level.
What the evidence says
The long‑term thesis remains intact. HSIC trades above its 40‑week average, the 50‑day SMA sits at $86.09, and the 52‑week range shows the price only 4.08 % below the high of $90.86, indicating that the uptrend is still in place. The recent price pullback to $87.16 is a modest correction within that broader context.
For the next two to six weeks the balance of evidence leans positive, but with medium conviction. The assessment cites two of four conviction points: the daily trend aligns with the weekly uptrend, and the stock is leading the S&P 500 by 4.0 % over 50 days. However, the stock is lagging XLV by 5.6 % over the same span, and the breakout math does not meet a 3‑to‑1 reward‑to‑risk ratio, which caps conviction at medium. The strongest counter‑argument is the revenue miss and the pressure on discretionary dental services, which could keep the stock from sustaining a clean breakout.
Levels that matter
The structure holds above the 50‑day SMA at $86.09; a close below that would be the first crack. The trend would be considered ended if price falls beneath the swing‑zone support at $82.66, a level that also triggers a weekly‑close rule for picture change.
The breakout target is a daily close above $87.84 on volume above the 20‑day average. If that occurs, the first price objective is $89.31, a swing‑zone level offering a reward‑to‑risk of 0.6. The next target is the 52‑week high of $90.86, with a reward‑to‑risk of 1.2. Because the math does not achieve a 3‑to‑1 ratio, a price move to $92.5 would be needed to reach that threshold.
What would change the picture
A weekly close below the swing‑zone support at $82.66 would alter the current outlook, signaling that the weekly trend has broken and the picture would shift to a down‑trend scenario. A material change in earnings guidance—such as a downgrade of the 2026 EPS outlook—would also reset the narrative.
What to watch
- Next earnings release: November 3, focus on revenue versus guidance and discretionary dental spend.
- Sector catalysts: any macro‑level shift in dental discretionary spending or orthodontics market growth, as reported in recent GlobeNewswire releases.
- Valuation: consensus “buy” with a mean target of $96.6, representing a roughly 10 % discount to the average analyst price target.